What we are up to:

Testing for Clostridioides difficile and its disease

C. difficile causes 5-15% of hospital-acquired diarrheas and a growing number of community acquired diarrheas.  The infection can also be asymptomatic with carriage occurring frequently.  Each testing method has its strengths and weaknesses, but a multistep algorithm combines the sensitivity of a screen with the specificity of a toxin test to optimize patient care, minimize overdiagnosis,Continue reading

January 3, 2022

Managing the four-prong threat of CDI, antibiotics, the flu season and COVID-19

A recently published paper, Managing the four-prong threat of CDI, antibiotics, the flu seasons, and COVID -19, discusses the impact of COVID-19 on C. difficile infection rates.  Due to the pandemic,  health care facilities have adopted numerous mitigation procedures against COVID – 19 which have also reduced influenza rates and helped to lower the rate of hospital-acquired infections such as … Continue reading

August 16, 2021

The role of intestinal inflammation in C. difficile disease

In a recently published article written by Dr. David Lyerly and Jodie Lee, the role of intestinal inflammation is explored as it relates to C. difficile infection. The authors also note that inflammation correlates with disease severity. The complete article can be found here:… Continue reading

March 26, 2021

TECHLAB to Supply the New River Valley COVID-19 Task Force with Essential Reagents to Expand COVID-19 Testing

BLACKSBURG, Va., November 2, 2020 – TECHLAB® Inc., a leader in infectious disease diagnostics, today announced it has partnered with the New River Valley COVID-19 Task Force to cost-effectively expand future COVID-19 testing capacity. Under this agreement, the New River Health District secures access to TECHLAB’s analyte-specific reagents (ASRs) for SARS-CoV-2 for as little as … Continue reading

November 2, 2020